Tevogen AI Initiative Detailed

Tevogen Bio Inc. provided stockholders with details regarding its artificial intelligence initiative, Tevogen.AI™. The goal of Tevogen.AI™ is to incorporate machine learning and predictive modeling into Tevogen Bio’s ExacTcell™ technology. This is expected to enhance target identification and pre-clinical processes, strengthen the Company’s pipeline of immunotherapies, accelerate clinical timelines, and reduce development costs.

Tevogen.AI has two proprietary technologies with patents pending. An internal valuation of these assets is forthcoming. The Company intends to broaden its AI initiative beyond Tevogen Bio. The company is expanding its headquarters to accommodate dedicated facilities for the Tevogen.AI team of data scientists and engineers.

Strategic Partnerships

Microsoft is providing AI expertise, cloud computing infrastructure (Azure), and scientific resources to speed up drug discovery.

Databricks is providing data engineering and analytics capabilities to improve Tevogen’s AI models and enhance predictive accuracy.

Proprietary Tevogen.AI Technology

PredicTcell™

PredicTcell™ AI tools are capable of predicting immunologically active peptide complexes and their interactions with T cell receptors, improving precision in immunotherapy treatments. The PredicTcell platform uses algorithms which performs in-silico predictions for candidate selection across multiple diseases. It improves with each prediction through model tuning and reinforcement, helping expand the understanding of T cell receptor bindings, shortening the in-vivo process and expanding Tevogen Bio’s pipeline. Tevogen.AI has developed a database that processes millions of protein and peptide interactions spanning numerous diseases and the human genome.

AdapTcell™

AdapTcell™ uses algorithms to decode the interactions between human leukocyte antigens (HLA) and T cells. AdapTcell is expected to enhance the understanding of immune responses and open new therapeutic avenues. Algorithms built into AdapTcell perform experiments unlocking insights into genetics and proteomics, building an HLA specificity map. Tevogen.AI plans to expand into clinical trial patient identification using the information collected from its PredicTcell and AdapTcell platforms.

Tevogen will continue providing updates on the progress of Tevogen.AI.